Patent Expiry

Patent/Exclusivity Expiry: ORSERDU

Other upcoming events for RANI

Phase 3 ReadoutPhase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: ORSERDU — RANI Patent Expiry | BioSniper